Bacterial vaccines in clinical and preclinical development 2021
An overview and analysis
Overview
The World Health Organization’s (WHO) “An analysis of bacterial vaccines in preclinical and clinical development: 2021” is the first WHO analyses and report of vaccine candidates in preclinical and clinical development in 2021, in the context of antimicrobial resistance (AMR).
The analyses focuses on vaccine candidates in development against pathogens in the WHO Bacterial Priority Pathogens list, Clostridioides difficile and Mycobacterium tuberculosis. The analysis highlights 61 vaccine candidates in various stages of clinical development, and 94 candidates in the preclinical development.
Vaccines are powerful tools to prevent infections, and therefore have the potential to curb the spread of AMR infections and reduce the use of antimicrobials. The WHO vaccine pipeline report aims to improve the understanding around vaccines in development against AMR priority bacteria to guide action and investments. This report is part of the WHO efforts to inform sustainable investment in research and development of new medicines, diagnostic tools, and other interventions to control AMR.
All of the data contained in this report can be downloaded from the WHO Global Observatory on Health R&D
